Vilya

Vilya is a computational drug-design biotechnology company pioneering the de novo design of macrocycles — entirely new therapeutic molecules that do not exist in nature. Spun out of the Institute for Protein Design and built on Nobel Prize-winning computational protein-design research from scientific founder Dr. David Baker, Vilya uses AI-driven generative models to generate, predict, and validate novel, chemically diverse macrocycles in silico. Its pipeline advances orally bioavailable macrocycles that aim to combine the target selectivity of biologics with the convenience of small- molecule pills, opening previously untreatable disease areas across oncology and immunology (including an integrin alpha4beta7 program for IBD). Vilya is a private therapeutics company; it publishes no public developer API, SDKs, or developer portal.

Vilya is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Drug Discovery, Artificial Intelligence, and Computational Biology.

Vilya’s developer surface includes engineering blog, support, and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub
15.0/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyDrug DiscoveryArtificial IntelligenceComputational BiologyMacrocyclesTherapeuticsLife SciencesProtein Design

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 15.0/100 · emerging
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 4.2 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/vilya: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Vilya Domain Security

TLSv1.3 · DNSSEC · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 5

The organization behind the API

Website
Website
 About
About
 Blog
Blog
 Careers
Careers
 LinkedIn
LinkedIn

Source (apis.yml)

apis.yml Raw ↑ 
aid: vilya
name: Vilya
description: Vilya is a computational drug-design biotechnology company pioneering the de novo design of macrocycles — entirely
  new therapeutic molecules that do not exist in nature. Spun out of the Institute for Protein Design and built on Nobel Prize-winning
  computational protein-design research from scientific founder Dr. David Baker, Vilya uses AI-driven generative models to
  generate, predict, and validate novel, chemically diverse macrocycles in silico. Its pipeline advances orally bioavailable
  macrocycles that aim to combine the target selectivity of biologics with the convenience of small- molecule pills, opening
  previously untreatable disease areas across oncology and immunology (including an integrin alpha4beta7 program for IBD).
  Vilya is a private therapeutics company; it publishes no public developer API, SDKs, or developer portal.
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://vilya.ai/apple-touch-icon.png
url: https://raw.githubusercontent.com/api-evangelist/vilya/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- menlo-ventures
x-lead-investor: ARCH Venture Partners
x-scientific-founder: David Baker (Institute for Protein Design)
x-ceo: Cyrus Harmon
x-sector: biotechnology / computational drug discovery
x-api-surface: none
x-tier: profiled
x-tier-reason: real-company-no-api-surface
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Drug Discovery
- Artificial Intelligence
- Computational Biology
- Macrocycles
- Therapeutics
- Life Sciences
- Protein Design
apis: []
common:
- type: DomainSecurity
  url: security/vilya-domain-security.yml
- type: Website
  url: https://vilya.ai
- type: About
  url: https://vilya.ai/about
- type: Blog
  url: https://vilya.ai/news
- type: Careers
  url: https://vilya.ai/careers
- type: Support
  url: https://vilya.ai/contact
- type: PrivacyPolicy
  url: https://vilya.ai/privacy
- type: TermsOfService
  url: https://vilya.ai/terms
- type: LinkedIn
  url: https://www.linkedin.com/company/vilyatx/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1